Sign in Subscribe

targeted-therapy

A collection of 105 issues

First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor

Skip to content The CRC Digest ▸ TREATMENT First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor Verastem Oncology has dosed the first patient in a phase 2 registration-directed trial of VS-7375, an oral KRAS G12D inhibitor, for KRAS G12D-mutated metastatic colorectal cancer. (BioSpace) This content is informational

Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC A study found that liquid biopsy can guide rechallenge with anti-HER2 therapy in patients with HER2-amplified metastatic colorectal cancer. (JCO Precision Oncology) This content is informational only and does not constitute medical advice. Always

Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition

Skip to content The CRC Digest ▸ TREATMENT Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition A 60-year-old male patient diagnosed in 2019 with BRAF-mutant metastatic CRC and peritoneal metastases experienced an extraordinary response to MEK inhibitor-based treatment. (Frontiers in Oncology) This content

Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models

Skip to content The CRC Digest ▸ TREATMENT Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models Fruquintinib, an oral inhibitor of all three vascular endothelial growth factor receptors that has been approved for chemorefractory CRC, showed combined antitumor activity with TAS-102 in xenograft

Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology) This content is

Review Examines Resistance Mechanisms to Anti-EGFR Therapies

Skip to content The CRC Digest Review Examines Resistance Mechanisms to Anti-EGFR Therapies A review of cetuximab and panitumumab resistance found that intrinsic resistance often stems from pre-existing KRAS, NRAS, and BRAF mutations, while acquired resistance develops through clonal evolution under therapeutic pressure. (Pharmaceuticals) This content is informational only and

Spatial Tumor Variation May Explain HER2 Testing Discrepancies

Skip to content The CRC Digest ◇ RESEARCH Spatial Tumor Variation May Explain HER2 Testing Discrepancies A retrospective analysis of 1,343 colorectal cancer cases found that spatial intratumoral heterogeneity in HER2 overexpression contributes to discordance between immunohistochemistry/FISH and next-generation sequencing, with implications for HER2-targeted therapy selection. (Virchows Arch) This

DHODH Identified as Metabolic Vulnerability in PIK3CA-Mutant Colorectal Cancer

Skip to content The CRC Digest DHODH Identified as Metabolic Vulnerability in PIK3CA-Mutant Colorectal Cancer Preclinical research identifies dihydroorotate dehydrogenase (DHODH) as a selective metabolic dependency in PIK3CA-mutant CRC; DHODH inhibition reduces cancer cell self-renewal and tumor initiation by disrupting PI3K-AKT signaling. (Cell Reports) This content is informational only and

KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy

Skip to content The CRC Digest ◇ RESEARCH KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy Preclinical research shows that KRAS G12D inhibition with MRTX1133 remodels the tumor immune environment by reducing immunosuppressive cells and facilitating infiltration of natural killer and CD8+ T cells, reversing systemic immunosuppression and restoring

Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer A phase 1/2 trial testing copanlisib (a PIK3CA inhibitor) combined with nivolumab in metastatic microsatellite stable CRC did not meet its primary endpoint, with 0 of 17 PIK3CA-wildtype